Breast cancer can be subdivided into human epidermal growth factor receptor 2 (HER-2) positive and HER-2 negative breast cancer due to the important molecular marker HER-2, and around 10%–17% is defined as triple-negative breast cancer (TNBC) that is also negative for estrogen and progesterone receptors It confers a high risk of recurrence and mortality [1]. Here, ERBB2 is linked to triple-negative breast carcinoma.